Life Science Start-Ups: Tech Transfer Deals, September 2014
• By Deanna Kamienski, Beth Allan, Amanda Micklus, Maureen Riordan, and Steven Muntner
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfers column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced June through August 2014.
C2N licenses Alzheimer's detection technology from Univ. of Washington School of Medicine
C2N Diagnostics LLC (developing assays to assist in neurodegenerative disease diagnosis and drug discovery) licensed exclusive rights to the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Instead of opting in on Phase II-ready PCSK9-targeted VERVE-102, Lilly will buy its partner for up to $1.3bn. Analysts call the deal a bargain for Lilly, but fair to Verve.
After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.
Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.
With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.
First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.
